MetaCap

BlossomHill Therapeutics (BLSM) vs Gyre Therapeutics (GYRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $460.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%GYRE-36.88%
+73%+14%-45%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%GYRE-36.88%
+66%+12%-42%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus GYRE key metrics
MetricBLSMGYRE
Share price$14.51$4.21
Market cap$461.20M$460.79M
1-day change+0.69%-6.86%
YTD return—-40.37%
1-year return—-44.24%
5-year return—-77.55%
Forward P/E—70.17
EPS (TTM)$-10.38$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$116.59M
Revenue growth (YoY)—+10.24%
Net income (latest FY)—$9.88M
Gross margin—95.35%
Operating margin—9.85%
Net margin—8.47%
52-week high$27.99$9.14
52-week low$11.02$3.97
Distance from 52-week high-48.16%-53.94%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+143.97%+343.47%
Average volume193.15K181.04K
Shares outstanding31.78M109.45M
Employees69625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

BLSM vs GYRE FAQ

Which is bigger, BlossomHill Therapeutics or Gyre Therapeutics?

BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $460.79M for Gyre Therapeutics (GYRE).

Are BlossomHill Therapeutics and Gyre Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons